The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical outcome of recombinant human soluble thrombomodulin (rTM) for patients with disseminated intravascular coagulation (DIC) complicating advanced solid cancer: Retrospective analysis.
Shin Takahashi
No relevant relationships to disclose
Kohta Ohuchi
No relevant relationships to disclose
Shunsuke Kato
No relevant relationships to disclose
Hideki Shimodaira
No relevant relationships to disclose
Yuichi Kakudo
No relevant relationships to disclose
Shoko Akiyama
No relevant relationships to disclose
Kozue Yoshida
No relevant relationships to disclose
Masatoshi Shiono
No relevant relationships to disclose
Yoshinari Okada
No relevant relationships to disclose
Shunsuke Sugiyama
No relevant relationships to disclose
Naoko Saito
No relevant relationships to disclose
Jin Lee
No relevant relationships to disclose
Takayuki Oishi
No relevant relationships to disclose
Hidekazu Takahashi
No relevant relationships to disclose
Yuki Yoshino
No relevant relationships to disclose
Chikashi Ishioka
Research Funding - Asahi Kasei ; Chugai Pharma; Novartis; Taiho Pharmaceutical; Yakult Honsha